[Efficacy and safety of № I Empirical Prescription for Chronic Prostatitis in the treatment of type Ⅲ refractory chronic prostatitis].

Autor:	Zhu Y; Department of Andrology, Yancheng Hospital of Traditional Chinese Medicine, Nanjing University of Chinese Medicine, Yancheng, Jiangsu 224001, China., Ge XD; Department of Andrology, Yancheng Hospital of Traditional Chinese Medicine, Nanjing University of Chinese Medicine, Yancheng, Jiangsu 224001, China., Shi Y; Department of Andrology, Yancheng Hospital of Traditional Chinese Medicine, Nanjing University of Chinese Medicine, Yancheng, Jiangsu 224001, China., Guo JH; Department of Andrology, Yancheng Hospital of Traditional Chinese Medicine, Nanjing University of Chinese Medicine, Yancheng, Jiangsu 224001, China., Liu ZJ; Department of Andrology, Yancheng Hospital of Traditional Chinese Medicine, Nanjing University of Chinese Medicine, Yancheng, Jiangsu 224001, China., Zeng QQ; Department of Integrated Chinese and Western Medicine, Jiangsu Health Vocational College, Nanjing, Jiangsu 210029, China.
Jazyk:	čínština
Zdroj:	Zhonghua nan ke xue = National journal of andrology [Zhonghua Nan Ke Xue] 2018 Jul; Vol. 24 (7), pp. 640-644.
Abstrakt:	Objective: To evaluate the efficiency and safety of № I Empirical Prescription for Chronic Prostatitis (№ I EPCP) in the treatment of type Ⅲ refractory chronic prostatitis. Methods: We randomly assigned 53 cases of type Ⅲ refractory chronic prostatitis with damp-heat and blood stasis to an experimental and a control group to receive № I EPCP at 1 dose per day and saw palmetto extract at 160 mg bid), respectively, all for 8 weeks. Before and after 4 and 8 weeks of treatment, we obtained The National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI) scores, Traditional Chinese Medicine Syndrome Scores (TCMSS), maximum urinary flow rate (Qmax), average urinary flow rate (Qavg), Hamilton Depression Rating Scale (HAMD) scores and Hamilton Anxiety Rating Scale (HAMA) scores, and compared them between the two groups of patients. Results: Totally 48 of the patients completed the medication and follow-up, 25 in the experimental and 23 in the control group. Compared with the baseline, the NIH-CPSI scores after 8 weeks of treatment were significantly decreased in the experimental (27.82 ± 7.25 vs 15.46 ± 4.77, P <0.05) and the control group (25.98 ± 6.47 vs 21.06 ± 5.74, P <0.05), and so were the TCMSSs (24.64 ± 9.82 vs 16.42 ± 6.33 and 9.15 ± 3.74, P <0.05, and 23.67 ± 8.73 vs 18.55 ± 5.92 and 13.48 ± 4.45, P <0.05); the Qmax at 8 weeks were dramatically increased in the experimental group (［18.45 ± 7.81］ vs ［23.44 ± 8.73］ ml/s, P <0.05) and the control (［17.58 ± 6.92］ vs ［21.26 ± 8.32］ ml/s, P <0.05), and so was the Qavg (［11.27 ± 5.33］ vs ［16.51 ± 7.36］ ml/s, P <0.05 and ［10.66 ± 5.82］ vs ［13.44 ± 6.16］ ml/s, P <0.05); the HAMD scores were remarkably reduced in the experimental group (22.74 ± 6.37 vs 17.62 ± 5.71 and 12.54 ± 5.22, P <0.05) and the control (23.55 ± 7.14 vs 22.34 ± 6.88 and 21.62 ± 5.63, P <0.05), and so were the HAMA scores (21.37 ± 7.15 vs 18.42 ± 6.35 and 14.63 ± 7.11, P <0.05 and 20.54 ± 6.77 vs 19.87 ± 6.24 and 19.42 ± 7.04, P <0.05). No obvious adverse reactions were observed in either of the two groups during the medication. Conclusions: № I EPCP deserves promotion and clinical application for its definite effectiveness and safety in the treatment of type Ⅲ refractory chronic prostatitis with damp-heat and blood stasis.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu